تمایل به پرداخت برای واکسن کرونا ویروس 2019: یک مطالعه مروری

1.Huang, C.;Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506.

2.Yang, Y.; Peng, F.;Wang, R.; Guan, K.; Jiang, T.; Xu, G.; Sun, J.; Chang, C. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun. 2020, 109, 102434.

3.Imai, N.; Gaythorpe, K.A.; Abbott, S.; Bhatia, S.; Van Elsland, S.; Prem, K.; Liu, Y.; Ferguson, N.M. Adoption and impact of non-pharmaceutical interventions for COVID-19. Wellcome Open Res. 2020, 5, 59.

4.Miller, I.F.; Becker, A.D.; Grenfell, B.T.; Metcalf, C.J.E. Disease and healthcare burden of COVID-19 in the United States. Nat. Med.2020, 26, 1212–1217.

5. Sarun Charumilind, M.C.; Lamb, J.; Sabow, A.; Wilson, M. When Will the COVID-19 Pandemic End? McKinsey& Company:New York, NY, USA, 2021

6.2020-21, C. Report 9—Impact of Non-Pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand. Available online: https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-impactof-npis-on-covid-19/ (accessed on 12 March 2021).

7.Fong, M.W.; Gao, H.; Wong, J.Y.; Xiao, J.; Shiu, E.Y.; Ryu, S.; Cowling, B.J. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings—Social Distancing Measures. Emerg. Infect. Dis. 2020, 26, 976–984.

8.Davies, N.G.; Kucharski, A.J.; Eggo, R.M.; Gimma, A.; Edmunds, W.J. Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: A modelling study. Lancet Public Health 2020, 5, e375–e385

9. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020 Mar 21; 395(10228):931-4.

10- Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines (Basel). 2020 Mar 29; 8(2).

11. Immunization Financing a Resource Guide for Advocates, Policymakers and Program Managers. Available from: https://r4d.org/resources/immunizationfinancing-resource-guide-advocates-policymakers-program-managers/ (accessed

On 2020/7/17).

12. Nuño, M.; Chowell, G.; Gumel, A. Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: Scenarios for the US, UK and the Netherlands. J. R. Soc. Interface 2006, 4, 505–521
13. Ten Threats to Global Health in 2019. 2019. Available online: https://www.who.int/news-room/spotlight/ten-threats-to-globalhealth-in-2019 (accessed on 10 January 2019).

14.Larson, H.J.; Jarrett, C.; Schulz,W.S.; Chaudhuri, M.; Zhou, Y.; Dube, E.; Schuster, M.; MacDonald, N.E.;Wilson, R. Measuring vaccine hesitancy: The development of a survey tool. Vaccine 2015, 33, 4165–4175

15. Lazarus, J.V.; Ratzan, S.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2020, 1–4.

16.Mokhber Alsafa L, Forqani S, Hagheghe S,Afkhamnia M. Satisfaction and attitude of farmers in

industrial farms regarding Brucellosis Sharbon and Tab barfaki produced by Razi Institute (2014 - 2015). Journal of Veterinary Research and Biological Products (Research and Construction) 2017; 2: 119 - 127.Doi: 0.22034/vj.2017.109229.

17.Nick H, Shogren Jason F and Ben W.Environmental Economics in Theory and Practice. 2th

Edition, Basingstoke: Palgrave Macmillan; 2007 8. Yulan L, Zheng L, Fei H, Huilin Ch, Xi L, Gregory D, et al. HPV vaccination intent and willingness to pay for 2 – 4, and 9 – valent HPV vaccines: A study of adult women aged 27 – 45 years in China. Journal of Vaccine 2020; 38: 3021 – 3030. Doi: 10.1016/j.vaccine.2020.2.042.

18.Lusk JL, Hudson D. Willingness-to-pay estimates and their relevance to agribusiness decision making. Rev Agric Econ 2004; 26:152–69. https://doi.org/10.1111/j.1467-9353.2004.00168.x.

19.Ughasoro MD, Esangbedo DO, Tagbo BN, Mejeha IC. Acceptability and willingness-to-pay for a hypothetical ebola.virus vaccine in Nigeria. PLoS Negl Trop Dis 2015; 9:1–15. https://doi.org/10.1371/journal.pntd.0003838

20.Cropper ML, Haile M, Lampietti J, Poulos C, Whittington D. The demand for a malaria vaccine: Evidence from Ethiopia. J Dev Econ 2004; 75:303–18. https://doi.org/10.1016/j.jdeveco.2003.02.006.

21. Godói IP, Sarmento TT, Reis EA, Gargano LP, Godman B, Acurcio FD, Alvares-Teodoro J, AA GJ, Ruas CM. Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications. Expert Review of Pharmacoeconomics & Outcomes Research. 2021 May 17.
22. Han K, Francis MR, Zhang R, Wang Q, Xia A, Lu L, Yang B, Hou Z. Confidence, acceptance and willingness to pay for the COVID-19 vaccine among migrants in Shanghai, China: a cross-sectional study. Vaccines. 2021 May;9(5):443.
23. Nguyen LH, Hoang MT, Nguyen LD, Ninh LT, Nguyen HT, Nguyen AD, Vu LG, Vu GT, Doan LP, Latkin CA, Tran BX. Acceptance and willingness to pay for COVID‐19 vaccines among pregnant women in Vietnam. Tropical Medicine & International Health. 2021 Oct;26(10):1303-13.
24. Catma S, Varol S. Willingness to pay for a hypothetical COVID-19 vaccine in the United States: A contingent valuation approach. Vaccines. 2021 Apr;9(4):318.
25. Qin W, Wang E, Ni Z. Chinese consumers’ willingness to get a COVID-19 vaccine and willingness to pay for it. Plos one. 2021 May 4;16(5):e0250112.
26. Arshad MS, Hussain I, Mahmood T, Hayat K, Majeed A, Imran I, Saeed H, Iqbal MO, Uzair M, Ashraf W, Usman A. A National Survey to Assess the COVID-19 Vaccine-Related Conspiracy Beliefs, Acceptability, Preference, and willingness to pay among the general population of Pakistan. Vaccines. 2021 Jul;9(7):720.
27. Adeli OA. Estimating willingness to pay for the Covid-19 vaccine using the conditional valuation method. Payesh (Health Monitor). 2021:0-.
28. García LY, Cerda AA. Contingent assessment of the COVID-19 vaccine. Vaccine. 2020 Jul 22;38(34):5424-9.
29. Berghea F, Berghea CE, Abobului M, Vlad VM. Willingness to pay for a for a potential vaccine against SARS-CoV-2/COVID-19 among adult persons.
30. Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS neglected tropical diseases. 2020 Dec 17;14(12): e0008961.
31. Banik, R., Islam, M., Pranta, M.U.R., Rahman, Q.M., Rahman, M., Pradhan, S., Driscoll, R., Hossain, S. and Sikder, M., 2021. Understanding the determinants of COVID-19 vaccination intention and willingness to pay: findings from a population-based survey in Bangladesh. BMC Infectious Diseases, 21(1), pp.1-15.
32. Zhang Y, Luo X, Ma ZF. Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China. Human vaccines & immunotherapeutics. 2021 Jun 3;17(6):1622-7.
33. Zhang Y, Luo X, Ma ZF. Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China. Human vaccines & immunotherapeutics. 2021 Jun 3;17(6):1622-7.
34. Vo NX, Nguyen TT, Van Nguyen P, Tran QV, Vo TQ. Using contingent valuation method to estimate adults’ willingness to pay for a future coronavirus 2019 vaccination. Value in health regional issues. 2021 May 1; 24:240-6.
35. Karam MM, Baki JA, Al-Hajje A, Sraj M, Awada S, Salameh P, Ajrouche R. Willingness to Pay for a Coronavirus Vaccine and Its Associated Determinants in Lebanon. Value in health regional issues. 2022 Jul 1; 30:18-25.
36. Wong LP, Alias H, Wong PF, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Human vaccines & immunotherapeutics. 2020 Sep 1;16(9):2204-14.
37. Cerda AA, García LY. Willingness to pay for a COVID-19 vaccine. Applied health economics and health policy. 2021 May;19(3):343-51.
38. Caple A, Dimaano A, Sagolili MM, Uy AA, Aguirre PM, Alano DL, Camaya GS, Ciriaco BJ, Clavo PJ, Cuyugan D, Fermo CF. Interrogating COVID-19 vaccine hesitancy in the Philippines with a nationwide open-access online survey. medRxiv. 2021 Jan 1.
39. Das U, Rathore U, Pal R. On willingness to pay for Covid-19 vaccines: a case study from India. Human vaccines & immunotherapeutics. 2021 Oct 24:1-0.
40. Catma S, Reindl D. Parents’ willingness to pay for a COVID-19 vaccine for themselves and their children in the United States. Human Vaccines & Immunotherapeutics. 2021 Sep 2;17(9):2919-25.
41. Carpio CE, Sarasty O, Hudson D, Macharia A, Shibia M. The demand for a COVID-19 vaccine in Kenya. Human Vaccines & Immunotherapeutics. 2021 Oct 3;17(10):3463-71.
42. Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, Setiawan AM, Rajamoorthy Y, Sofyan H, Vo TQ, Hadisoemarto PF. Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia. Human vaccines & immunotherapeutics. 2020 Dec 1;16(12):3074-80.
43. Dong D, Xu RH, Wong EL, Hung CT, Feng D, Feng Z, Yeoh EK, Wong SY. Public preference for COVID‐19 vaccines in China: A discrete choice experiment. Health Expectations. 2020 Dec;23(6):1543-78.
44. Borriello A, Master D, Pellegrini A, Rose JM. Preferences for a COVID-19 vaccine in Australia. Vaccine. 2021 Jan 15;39(3):473-9.
45. Leng A, Maitland E, Wang S, Nicholas S, Liu R, Wang J. Individual preferences for COVID-19 vaccination in China. Vaccine. 2021 Jan 8;39(2):247-54.
46. Sarasty O, Carpio CE, Hudson D, Guerrero-Ochoa PA, Borja I. The demand for a COVID-19 vaccine in Ecuador. Vaccine. 2020 Dec 3;38(51):8090-8.
47. Adigwe OP. COVID-19 vaccine hesitancy and willingness to pay: Emergent factors from a cross-sectional study in Nigeria. Vaccine: X. 2021 Dec 1;9:100112.
48. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). Published online at OurWorldInDataorg Retrieved from: 'https://ourworldindataorg/coronavirus' [Online Resource]. 2020

49.Storlie CB, Pollock BD, Rojas RL, Demuth GO, Johnson PW, Wilson PM, et al., editors. Quantifying the Importance of COVID-19 Vaccination to Our Future Outlook. Mayo Clinic Proceedings; 2021: Elsevier.

50.Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nature Medicine. 2021; 27(8): 91338-.

51.COVID C, Force RVT. Building Confidence in COVID-19 Vaccines Among Your Patients. 2021

52.Burki T. Vaccine misinformation and social media. The Lancet Digital Health. 2019;1(6):e258-e9.

53. Viswanath K, Bekalu M, Dhawan D, Pinnamaneni R, Lang J, McLoud R. Individual and social determinants of COVID-19 vaccine uptake. BMC public health. 2021 Apr 28;21(1):818.
54. Davis R. COVID-19 Vaccine hesitancy, delay, and refusal: Insufficient knowledge, complacency, and distrust of the medical system. Review of Contemporary Philosophy. 2021(20):139-50.
55. Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ. Strategies for addressing vaccine hesitancy–A systematic review. Vaccine. 2015 Aug 14;33(34):4180-90.
56. Taylor S, Landry CA, Paluszek MM, Groenewoud R, Rachor GS, Asmundson GJ. A proactive approach for managing COVID-19: the importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV2. Frontiers in psychology. 2020 Oct 19;11:575950.